
Collaboration to develop a series of AI models for AI drug discovery
SyntheticGestalt K.K. (Tokyo, Japan, CEO Koki Shimada), a research and development company specializing in AI development in the life sciences, and Enamine Ltd ( (Khiwo, Ukraine, CEO Andrey Tolmachov), a global provider of building block compounds, screening compounds, and integrated drug discovery services, announced today the start of a collaboration to develop a series of AI models to enable AI drug discovery.
The model will be used for SyntheticGestalt's services to academia and pharmaceutical companies, as well as for the company's research and development activities. The service will be used for SyntheticGestalt's services to academia and pharmaceutical companies and for the company's R&D activities.
Enamine is the largest database of on-demand compounds and provides access to the Enamine REAL database, which contains information on 38 billion compounds.
SyntheticGestalt is adding the Enamine REAL database to its Drug Discovery service. Enamine synthesizes proposed compounds in as little as 3-4 weeks and provides high-quality pharmacological in vitro profiling data through in-house testing. Enamine synthesizes proposed compounds in as little as 3-4 weeks and provides high quality pharmacological in vitro profiling data through in-house testing, helping to streamline and shorten the drug discovery cycle.
In addition, SyntheticGestalt will use the data provided by Enamine to enhance its pre-learning model. The model, which is expected to be the world's largest based on the 3D structure of a compound, will be used to improve the predictive accuracy of the company's machine learning models.
The model will also be proposed for collaborative research for other pharmaceutical companies. Details of the model and its performance will be presented at NVIDIA's annual NVIDIA GTC Japan AI Day event in March 2024.
Iaroslava Kos, Director of Business Development at Enamine, comments
The potential of AI/ML-assisted computer-aided design in the discovery of new drugs cannot be underestimated. Finding new active compounds by synthesizing just a handful of novel compounds is fantastic. We are pleased to enter into this collaboration with SyntheticGestalt and offer the talents and expertise of our scientists to help realize our mutual goals. We look forward to working together on our long-held dream of a cure."
Comments from Yukiteru Shimada, CEO of SyntheticGestalt
The application of machine learning in drug discovery research has long suffered from the problem of high performance on training data but low performance in real-world usage scenarios. The Enamine REAL database is ideal for our efforts because it is the largest and most trusted set of on-demand compounds on the market. We believe that just as large-scale pre-training has revolutionized large-scale language models (LLMs), we can enable a giant leap forward in AI drug discovery with the world's largest pre-training model developed in-house."
About SyntheticGestalt
SyntheticGestalt is an artificial intelligence research and development company specializing in the application of AI to drug discovery and other life science fields. Utilizing its proprietary artificial intelligence technology, SyntheticGestalt conducts research and development focused on the discovery of useful substances.
The AI platform used in this study is cloud-based, has a scalable structure, and can make predictions on large libraries, allowing prediction of physicochemical properties, ADME/ Tox properties, enzyme functions, etc.
SyntheticGestalt welcomes open innovation through collaboration with public institutions and private companies.
| name of company | SyntheticGestalt Corporation |
| Establishment | December 2018 |
| Location | 1-6 La Keyaki, Naito-cho, Shinjuku-ku, Tokyo |
| representative | Kouki Shimada |
| uniform resouce locator | https://syntheticgestalt.com/ |
About SyntheticGestalt Drug Discovery Services
SyntheticGestalt offers a web service that proposes solutions to ADME/Tox and physicochemical property problems for Hit ~ Lead compounds based on proprietary machine learning models. https://drugdiscovery.syntheticgestalt.com/
About Enamine
Enamine is a science-driven, integrated drug discovery contract research organization with unique partnering opportunities in the discovery of new compound space. The company combines access to in-house produced screening compounds (4 million compounds in stock) and compound building blocks (300,000 compounds in stock) with a comprehensive platform that includes integrated drug discovery services to advance and accelerate drug discovery efforts.
| name of company | Enamine Ltd. |
| Establishment | 1991 |
| Location | 7 Deer Park Dr Monmouth Junction, NJ, 08852, US |
| representative | CEO Andrey Tolmachov |
| Business Overview | Chemical Manufacturing |
| uniform resouce locator | https://enamine.net |
About Enamine REAL Database
The EnamineREAL® database (REadily AccesibLe) is a collection of over 38 billion molecules that can be synthesized and delivered by Enamine extremely quickly (3-4 weeks), highly feasible (>80%), and inexpensive. REAL compounds are synthesized using 167 different synthesized by parallel chemistry utilizing 137,000 compound building blocks via protocols and are the basis for Enamine's approach to designing on-demand compounds with maximum success rates.









